You are the head of corporate acquisitions team at a major biotech company in Atlanta, Georgia. Your team has identified a couple of attractive acquisition targets that you would like to recommend to the Board of Directors for consideration. However, before you make a recommendation, you want to make sure that none of the acquisitions will raise any regulatory issues. In order to evaluate all potential regulatory issues, which one of the following analytical actions should you have your team complete prior to making any recommendations?
a. A thorough analysis of the provisions of the Securities Act and the Securities Exchange Act.
b. A thorough analysis of the provisions of the Robinson-Patman Act and the Nutrition Labeling and Education Act.
c. A thorough analysis of the provisions of the Dodd-Frank Act and the Sarbanes-Oxley Act.
d. A thorough analysis of the provisions of the Celler-Kefauver Act, the Clayton Act, and the Sherman Antitrust Act.
e. A thorough analysis of the provisions of the Lanham Act and the Wheeler-Lea Act.